{"id":"W2951608335","doi":"10.1097/01.hs9.0000558816.91319.ce","title":"S149 FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION‐FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Minimal residual disease; Gastroenterology; Venetoclax; Hazard ratio; Clinical endpoint; Obinutuzumab; Population; Surrogate endpoint; Progression-free survival; Oncology; Surgery; Confidence interval; Randomized controlled trial; Chronic lymphocytic leukemia; Bone marrow; Leukemia; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006860296,0.0003066998,0.0009351278,0.0001749137,0.0001473899,0.0004230052,0.0003564908,0.0004775422,0.003627976],"category_scores_gemma":[0.0005328521,0.000149264,0.000542109,0.0002425576,0.0002799584,0.000294571,0.0001668232,0.0006724896,0.0002764983],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004753096,"about_ca_system_score_gemma":0.0006394894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006796061,"about_ca_topic_score_gemma":0.002588141,"domain_scores_codex":[0.9997881,0.0001034086,0.00001433262,0.00002803428,0.0000244931,0.00004164565],"domain_scores_gemma":[0.9996622,0.00008294328,0.0001035798,0.00001632753,0.00001263905,0.0001224236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7773262,0.00865501,0.02627504,0.000777153,0.001069863,0.0001907471,0.0001451075,0.002176999,0.03362365,0.0001800334,0.002106648,0.1474735],"study_design_scores_gemma":[0.3610146,0.4729441,0.1476825,0.0001793491,0.001287677,0.001026352,0.0001132491,0.003058768,0.007069129,0.0002454304,0.00532871,0.00005020817],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972335,0.001745566,0.00008196112,0.00006010907,0.00002687157,0.0001062954,0.0001602861,0.00001446464,0.0005710328],"genre_scores_gemma":[0.9984327,0.0004499011,0.0001905092,0.00009820687,0.00003337722,0.0001072173,0.0002770363,0.00000303493,0.0004081286],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003627976,"threshold_uncertainty_score":0.01213682,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0093089771667384,"score_gpt":0.2535555672772715,"score_spread":0.2442465901105331,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}